Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan Inhalations for Non-Cystic Fibrosis Bronchiectasis
NCT04278040Phase 2Unknown
- Sponsor
- Research Institute of Pulmonology
- Start
- Jun 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in Non-cystic fibrosis bronchiectasis (NCFB), sponsored by Research Institute of Pulmonology. Primary endpoint: Frequency of drug-related side effects at 6 months. Status: unknown.
02
Drugs
melphalan
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT04278040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278040.